{
  "id": 20700323,
  "title": "Revolution Medicines senior advisor Stephen Kelsey sells $4.5M",
  "url": "https://urgent.news/2026/11/19/revolution-medicines-senior-advisor-stephen-kelsey-sells-4-5m",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-19T04:01:12.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/revolution-medicines-senior-advisor-stephen-kelsey-sells-45m-93CH-5037685"
  },
  "original_language": "en",
  "account": null,
  "summary": "Revolution Medicines senior advisor Stephen Kelsey sold 27,160 shares of the company's stock on November 16, 2026, for approximately $4.5 million, according to a report by Investing.com. The sale took place under a pre-arranged 10b5-1 trading plan and occurred as the stock price was trading at $159.82, down 9.4% over the previous week. Despite this recent decline, Revolution Medicines has seen a remarkable 127% return over the past year and a year-to-date gain exceeding 100%. Prior to the sales, Kelsey exercised options to acquire shares at $18.56 per share, totaling $504,089. Following these transactions, Kelsey now directly holds 286,307 shares of Revolution Medicines common stock, including 65,613 restricted stock units, and beneficially owns 108,640 derivative securities in the form of stock options. Analysts have noted that the stock appears undervalued, trading below its Fair Value.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}